To prove that Tregs indeed control anti-tumor CD4+ T-cell functions in the FBL-3 model, we analyzed numbers of tumor-specific CD4+ T cells, their cytokine production and cytotoxic activity after Treg ablation with or without additional CD8+ T-cell depletion. This evidence concerns the gene CD4 and neoplasm.